Grufity logoGrufity logo

10x Genomics, Inc. Stock Research

TXG

50.23USD+1.19(+2.43%)Market Closed

Market Summary

USD50.23+1.19
Market Closed
2.43%

TXG Alerts

TXG Stock Price

TXG RSI Chart

TXG Valuation

Market Cap

5.8B

Price/Earnings (Trailing)

-34.86

Price/Sales (Trailing)

11.2

EV/EBITDA

-40.84

Price/Free Cashflow

-35.01

TXG Price/Sales (Trailing)

TXG Profitability

Operating Margin

76.69%

EBT Margin

-31.36%

Return on Equity

-20.6%

Return on Assets

-16.13%

Free Cashflow Yield

-2.86%

TXG Fundamentals

TXG Revenue

Revenue (TTM)

516.4M

Revenue Y/Y

8.85%

Revenue Q/Q

19.2%

TXG Earnings

Earnings (TTM)

-166.0M

Earnings Y/Y

6.69%

Earnings Q/Q

58.93%

Price Action

52 Week Range

23.8183.34
(Low)(High)

Last 7 days

-0.2%

Last 30 days

2.8%

Last 90 days

46.7%

Trailing 12 Months

-27.2%

TXG Financial Health

Current Ratio

4.85

TXG Investor Care

Shares Dilution (1Y)

2.38%

Diluted EPS (TTM)

-1.46

Peers (Alternatives to 10x Genomics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.9B
6.8B
-7.12% -2.94%
31.04
5.68
8.37% 3.64%
34.8B
4.6B
9.07% -35.87%
-7.89
7.58
1.28% -677.95%
32.3B
3.9B
0.30% 5.82%
37.04
8.24
5.43% 13.46%
17.7B
3.0B
-6.58% -7.74%
25.05
5.97
6.68% 2.15%
16.1B
3.3B
-0.99% -28.86%
28.31
4.87
-34.64% -39.65%
MID-CAP
SMALL-CAP
2.2B
128.3M
3.11% -0.62%
-6.93
16.97
-1.69% -73.40%
1.2B
185.3M
-4.53% -36.18%
-6.03
6.51
20.06% 3.42%
404.1M
127.3M
-11.64% -74.22%
-2.53
3.18
-12.28% -38.43%
394.4M
105.5M
-10.11% -62.94%
-4.08
3.74
-4.55% -67.63%
326.9M
27.8M
-22.54% -54.36%
-2.47
11.76
54.62% -83.06%
255.3M
138.6M
-29.45% -81.04%
-7.6
1.84
32.30% -57.86%
130.5M
113.3M
8.01% -46.55%
-13.71
1.15
-4.68% -3204.17%
121.4M
65.0M
-18.24% -68.45%
-1.07
1.87
-23.92% -73.73%
57.9M
54.1M
-2.96% -46.49%
536.06
1.07
21.80% -72.38%

Financials for 10x Genomics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue2.5%516,409,000503,707,000497,932,000499,165,000490,490,000
Gross Profit0.9%396,023,000392,550,000392,634,000416,656,000416,399,000
Operating Expenses1.9%563,967,000553,228,000529,195,000500,428,000468,652,000
  S&GA Expenses3.1%298,300,000289,290,000277,965,000267,331,000257,560,000
EBITDA0.2%-136,127,000-136,357,000-113,325,000-60,963,000-31,731,000
EBITDA Margin2.6%-0.26-0.27-0.23-0.12-0.06
Earnings Before Taxes-0.3%-161,971,000-161,553,000-138,166,000-84,293,000-53,715,000
EBT Margin2.2%-0.31-0.32-0.28-0.17-0.11
Interest Expenses-16.2%476,000568,000673,000773,000866,000
Net Income0.7%-166,000,000-167,234,000-142,491,000-89,085,000-58,223,000
Net Income Margin3.2%-0.32-0.33-0.29-0.18-0.12
Free Cahsflow-2.6%-165,267,000-161,069,000-161,376,000-128,642,000-122,651,000
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets3.3%1,0299961,0021,0031,019
  Current Assets0.9%635629666697748
    Cash Equivalents-5.9%227242282320596
  Inventory3.8%82.0079.0071.0064.0060.00
  Net PPE12.3%289258223190169
  Goodwill0%5.005.005.005.005.00
Liabilities1.3%223220218197201
  Current Liabilities3.2%13112711894.00110
Shareholder's Equity3.9%806776784807818
  Retained Earnings-1.7%-1,029-1,012-970-905-863
  Additional Paid-In Capital2.6%1,8391,7931,7581,7151,681
Accumulated Depreciation40.4%69.0049.00---
Shares Outstanding0.9%115114114113113
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations19.1%-33.61-41.52-58.18-38.09-21.37
  Share Based Compensation11.5%13712311510696.00
Cashflow From Investing-1.6%-350-345-332-319-106
Cashflow From Financing-19.8%16.0020.0024.0034.0035.00

Risks for TXG

What is the probability of a big loss on TXG?

86.6%


Probability that 10x Genomics stock will be more than 20% underwater in next one year

64.0%


Probability that 10x Genomics stock will be more than 30% underwater in next one year.

58.1%


Probability that 10x Genomics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TXG drawdown profile look like?

Y-axis is the maximum loss one would have experienced if 10x Genomics was unfortunately bought at previous high price.

Drawdowns

Returns for TXG

Cumulative Returns on TXG

-4.2%


3-Year Cumulative Returns

Which funds bought or sold TXG recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
BAILLIE GIFFORD & CO
added
1.88
72,998,400
313,465,000
0.33%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.05
76,760
353,760
-%
2023-03-06
Rockefeller Capital Management L.P.
added
319
358,000
439,000
-%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
added
4.78
332,981
1,309,980
0.08%
2023-02-28
Voya Investment Management LLC
added
0.01
282,450
1,290,450
-%
2023-02-24
NATIXIS
new
-
74,155
74,155
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
555,000
2,547,000
0.03%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
reduced
-8.51
1,402
9,402
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-
-25,000
-
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
reduced
-7.41
-89.00
911
-%

1–10 of 45

Latest Funds Activity

Are funds buying TXG calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own TXG
No. of Funds

10x Genomics News

Best Stocks

Allworth Financial LP owns $1.88 million in 10x Genomics, Inc ....

Best Stocks,
2 days ago

Nasdaq

Zacks Investment Research

Schedule 13G FIlings of 10x Genomics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
venrock associates vi, l.p.
4.9%
4,828,247
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.81%
8,420,011
SC 13G/A
Feb 08, 2023
morgan stanley
10.4%
9,894,979
SC 13G/A
Feb 01, 2023
blackrock inc.
5.6%
5,319,179
SC 13G/A
Jan 18, 2023
baillie gifford & co
9.00%
8,602,235
SC 13G/A
Sep 12, 2022
morgan stanley
10.9%
10,341,753
SC 13G/A
May 09, 2022
blackrock inc.
10.9%
10,227,673
SC 13G
Feb 14, 2022
venrock associates vi, l.p.
5.1%
4,828,247
SC 13G/A
Feb 09, 2022
vanguard group inc
8.25%
7,554,042
SC 13G/A

TXG Fair Value

10x Genomics fair value in different scenarios

The table shows the Fair Value estimates for 10x Genomics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

2.48

-95.06%

3.37

-93.29%

6.07

-87.92%

10.16

-79.77%

13.70

-72.73%
Current Inflation

2.42

-95.18%

3.20

-93.63%

5.55

-88.95%

9.05

-81.98%

12.07

-75.97%
Very High Inflation

2.33

-95.36%

3.00

-94.03%

4.93

-90.19%

7.75

-84.57%

10.19

-79.71%

Historical 10x Genomics Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of 10x Genomics

View All Filings
Date Filed Form Type Document
Mar 23, 2023
4
Insider Trading
Mar 23, 2023
4
Insider Trading
Mar 23, 2023
4
Insider Trading
Mar 23, 2023
4
Insider Trading
Mar 16, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Feb 24, 2023
4
Insider Trading
Feb 24, 2023
4
Insider Trading
Feb 24, 2023
4
Insider Trading
Feb 16, 2023
10-K
Annual Report

Latest Insider Trading transactions for TXG

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-21
Saxonov Serge
acquired
-
-
36,387
chief executive officer
2023-03-21
Hindson Benjamin J.
acquired
-
-
36,387
see remarks
2023-03-21
Wilbur James
acquired
-
-
14,555
chief commercial officer
2023-03-21
McAnear Justin J.
acquired
-
-
25,991
chief financial officer
2023-03-14
Saxonov Serge
sold
-97,755
48.8779
-2,000
chief executive officer
2023-03-07
Saxonov Serge
gifted
-
-
-260
chief executive officer
2023-02-22
Saxonov Serge
sold
-92,689
47.7533
-1,941
chief executive officer
2023-02-22
McAnear Justin J.
sold
-59,452
47.7533
-1,245
chief financial officer
2023-02-22
Hindson Benjamin J.
sold
-83,186
47.7533
-1,742
see remarks
2022-12-14
Hindson Benjamin J.
acquired
172,701
5.04
34,266
see remarks

1–10 of 50

Serge Saxonov
1240
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Revenue$ 516,409$ 490,490$ 298,845
Cost of revenue120,38674,09158,468
Gross profit396,023416,399240,377
Operating expenses:   
Research and development265,667211,752123,375
In-process research and development00447,548
Selling, general and administrative298,300257,560202,326
Accrued contingent liabilities0(660)1,270
Total operating expenses563,967468,652774,519
Loss from operations(167,944)(52,253)(534,142)
Other income (expense):   
Interest income6,6472061,532
Interest expense(476)(866)(1,682)
Other (expense) income, net(198)(802)1,337
Loss on extinguishment of debt00(1,521)
Total other income (expense)5,973(1,462)(334)
Loss before provision for income taxes(161,971)(53,715)(534,476)
Provision for income taxes4,0294,5088,255
Net loss$ (166,000)$ (58,223)$ (542,731)
Net loss per share, basic (in dollars per share)$ (1.46)$ (0.53)$ (5.37)
Net loss per share, diluted (in dollars per share)$ (1.46)$ (0.53)$ (5.37)
Weighted-average shares used to compute net loss per share, basic (in shares)113,858,684110,347,937101,151,675
Weighted-average shares used to compute net loss per share, diluted (in shares)113,858,684110,347,937101,151,675

TXG Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 219,746$ 587,447
Marketable securities210,2380
Restricted cash2,6331,028
Accounts receivable, net104,21185,254
Inventory81,62959,966
Prepaid expenses and other current assets16,57813,896
Total current assets635,035747,591
Property and equipment, net289,328169,492
Restricted cash4,9747,598
Operating lease right-of-use assets69,88260,918
Goodwill4,5114,511
Intangible assets, net22,85825,397
Other noncurrent assets2,3923,319
Total assets1,028,9801,018,826
Current liabilities:  
Accounts payable21,59917,351
Accrued compensation and related benefits32,67531,626
Accrued expenses and other current liabilities59,77950,909
Deferred revenue7,8675,340
Operating lease liabilities9,0375,131
Total current liabilities130,957110,357
Accrued license fee, noncurrent05,814
Operating lease liabilities, noncurrent86,13976,847
Other noncurrent liabilities6,1418,240
Total liabilities223,237201,258
Commitments and contingencies (Note 7)
Stockholders' equity:  
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2022 and December 31, 202100
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 115,195,009 (Class A 96,527,754, Class B 18,667,255) and 112,514,977 (Class A 92,868,512, Class B 19,646,465) shares issued and outstanding as of December 31, 2022 and 202122
Additional paid-in capital1,839,3971,680,865
Accumulated deficit(1,029,321)(863,321)
Accumulated other comprehensive income (loss)(4,335)22
Total stockholders’ equity805,743817,568
Total liabilities and stockholders’ equity$ 1,028,980$ 1,018,826